To functionally validate the role of NGFR-ERK1/2 signaling in PHOX1-mediated GC progression, we conducted comprehensive rescue experiments using siRNA against NGFR and the ERK1/2 inhibitor SCH772984 (ERKi). The gene discussed is MAPK3; the disease is gastric cancer.